SLV Share Price | Selvita SA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Selvita SA with Similar Stocks

Mabion SA Pure Biologics SA GenXone SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 5.35%

The company has been able to generate a Return on Capital Employed (avg) of 5.35% signifying low profitability per unit of total capital (equity and debt)

High Debt Company with a Debt to Equity ratio (avg) at times

High Debt company with Weak Long Term Fundamental Strength

The company has declared Negative results for the last 4 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 817 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.39

Return on Equity

-0.92%

Price to Book

2.58

Revenue and Profits:

Net Sales:

90 Million

(Quarterly Results - Mar 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.09%

6 Months

31.61%

1 Year

-4.2%

2 Years

-27.23%

3 Years

-48.02%

4 Years

-43.03%

5 Years

-22.4%

Selvita SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.61%

EBIT Growth (5y)

-21.24%

EBIT to Interest (avg)

4.94

Debt to EBITDA (avg)

1.60

Net Debt to Equity (avg)

0.40

Sales to Capital Employed (avg)

0.76

Tax Ratio

49.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.35%

ROE (avg)

10.42%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

EV to EBIT

125.73

EV to EBITDA

14.16

EV to Capital Employed

EV to Sales

1.78

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -7.19% vs 10.19% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -127.78% vs 50.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "90.30",
          "val2": "97.30",
          "chgp": "-7.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "13.20",
          "val2": "19.50",
          "chgp": "-32.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "2.80",
          "chgp": "-17.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "3.60",
          "chgp": "-127.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7.60%",
          "val2": "59.50%",
          "chgp": "-6.71%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1.44% vs -3.80% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -108.73% vs 147.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "342.00",
          "val2": "347.00",
          "chgp": "-1.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "48.90",
          "val2": "57.60",
          "chgp": "-15.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.40",
          "val2": "11.80",
          "chgp": "5.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.10",
          "val2": "69.90",
          "chgp": "-108.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12.40%",
          "val2": "35.00%",
          "chgp": "-4.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

90.30

97.30

-7.19%

Operating Profit (PBDIT) excl Other Income

13.20

19.50

-32.31%

Interest

2.30

2.80

-17.86%

Exceptional Items

0.00

Consolidate Net Profit

-1.00

3.60

-127.78%

Operating Profit Margin (Excl OI)

-7.60%

59.50%

-6.71%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -7.19% vs 10.19% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -127.78% vs 50.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

342.00

347.00

-1.44%

Operating Profit (PBDIT) excl Other Income

48.90

57.60

-15.10%

Interest

12.40

11.80

5.08%

Exceptional Items

0.00

Consolidate Net Profit

-6.10

69.90

-108.73%

Operating Profit Margin (Excl OI)

-12.40%

35.00%

-4.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -1.44% vs -3.80% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -108.73% vs 147.00% in Dec 2023

All Annual Results

Company CV

About Selvita SA

Selvita SA

Pharmaceuticals & Biotechnology

Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.

Company Coordinates

Company Details

Park Life Science, ul. Bobrzynskiego 14 , KRAKOW None : 30-348

Tel: 48 12 2974700

https://selvita.com/

Registrar Details